ANAPTYSBIO, INC. Increase Decrease In Operating Lease Liability
ANAPTYSBIO, INC. (ANAB) reported Increase Decrease In Operating Lease Liability of -$1.02 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-09-21
- ANAPTYSBIO, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$518.00K.
- ANAPTYSBIO, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$499.00K.
- ANAPTYSBIO, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$494.00K.
- ANAPTYSBIO, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$490.00K.
- ANAPTYSBIO, INC. increase decrease in operating lease liability for fiscal 2025 was -$1.93M.
- ANAPTYSBIO, INC. increase decrease in operating lease liability for fiscal 2024 was -$1.78M.
- ANAPTYSBIO, INC. increase decrease in operating lease liability for fiscal 2023 was -$1.64M.
- ANAPTYSBIO, INC. increase decrease in operating lease liability for fiscal 2022 was -$1.50M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$518.00K derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | -$1.02M 10-KT · filed 2026-09-21 | -$1.51M derived: sum of 3 quarters · filed 2026-09-21 | -$2.00M derived: sum of 4 quarters · filed 2026-09-21 |
| 2026-03-31 | -$499.00K 10-Q · filed 2026-05-12 | -$993.00K derived: sum of 2 quarters · filed 2026-09-21 | -$1.48M derived: sum of 3 quarters · filed 2026-09-21 | -$1.96M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-12-31 | -$494.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | -$984.00K derived: sum of 2 quarters · filed 2026-09-21 | -$1.46M derived: sum of 3 quarters · filed 2026-09-21 | -$1.93M 10-KT · filed 2026-09-21 |
| 2025-09-30 | -$490.00K derived: 10-Q 9 month − 10-KT 6 month · filed 2025-11-04 | -$969.00K derived: sum of 2 quarters · filed 2026-09-21 | -$1.43M 10-Q · filed 2025-11-04 | -$1.89M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-06-30 | -$479.00K derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | -$941.00K 10-KT · filed 2026-09-21 | -$1.40M derived: sum of 3 quarters · filed 2026-09-21 | -$1.85M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-03-31 | -$462.00K 10-Q · filed 2026-05-12 | -$919.00K derived: sum of 2 quarters · filed 2026-09-21 | -$1.37M derived: sum of 3 quarters · filed 2026-09-21 | -$1.81M derived: sum of 4 quarters · filed 2026-09-21 |
| 2024-12-31 | -$457.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | -$909.00K derived: sum of 2 quarters · filed 2026-09-21 | -$1.35M derived: sum of 3 quarters · filed 2026-09-21 | -$1.78M 10-KT · filed 2026-09-21 |
| 2024-09-30 | -$452.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$894.00K derived: sum of 2 quarters · filed 2025-11-04 | -$1.32M 10-Q · filed 2025-11-04 | -$1.74M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | -$442.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$868.00K 10-Q · filed 2025-08-06 | -$1.29M derived: sum of 3 quarters · filed 2026-03-03 | -$1.71M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$426.00K 10-Q · filed 2025-05-05 | -$846.00K derived: sum of 2 quarters · filed 2026-03-03 | -$1.26M derived: sum of 3 quarters · filed 2026-03-03 | -$1.67M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$420.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$838.00K derived: sum of 2 quarters · filed 2026-03-03 | -$1.25M derived: sum of 3 quarters · filed 2026-03-03 | -$1.64M 10-K · filed 2026-03-03 |
| 2023-09-30 | -$418.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$825.00K derived: sum of 2 quarters · filed 2024-11-05 | -$1.22M 10-Q · filed 2024-11-05 | -$1.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$407.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$798.00K 10-Q · filed 2024-08-05 | -$1.19M derived: sum of 3 quarters · filed 2025-02-27 | -$1.57M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$391.00K 10-Q · filed 2024-05-09 | -$780.00K derived: sum of 2 quarters · filed 2025-02-27 | -$1.16M derived: sum of 3 quarters · filed 2025-02-27 | -$1.54M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$389.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$772.00K derived: sum of 2 quarters · filed 2025-02-27 | -$1.15M derived: sum of 3 quarters · filed 2025-02-27 | -$1.50M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$383.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$757.00K derived: sum of 2 quarters · filed 2023-11-02 | -$1.12M 10-Q · filed 2023-11-02 | -$1.10M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | -$374.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$733.00K 10-Q · filed 2023-08-07 | -$713.00K derived: sum of 3 quarters · filed 2024-03-11 | -$555.00K derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | -$359.00K 10-Q · filed 2023-05-11 | -$339.00K derived: sum of 2 quarters · filed 2024-03-11 | -$181.00K derived: sum of 3 quarters · filed 2024-03-11 | -$286.00K derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $178.00K derived: sum of 2 quarters · filed 2024-03-11 | $73.00K derived: sum of 3 quarters · filed 2024-03-11 | -$72.00K 10-K · filed 2024-03-11 |
| 2021-09-30 | $158.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $53.00K derived: sum of 2 quarters · filed 2022-11-08 | -$92.00K 10-Q · filed 2022-11-08 | -$634.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$105.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$250.00K 10-Q · filed 2022-08-08 | -$792.00K derived: sum of 3 quarters · filed 2023-03-01 | -$1.01M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$145.00K 10-Q · filed 2022-05-04 | -$687.00K derived: sum of 2 quarters · filed 2023-03-01 | -$908.00K derived: sum of 3 quarters · filed 2023-03-01 | |
| 2020-12-31 | -$542.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$763.00K derived: sum of 2 quarters · filed 2023-03-01 | -$1.18M 10-K · filed 2023-03-01 | |
| 2020-09-30 | -$221.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$641.00K 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | -$420.00K 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | -$999.00K 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |